Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease.

ABSTRACT:

Introduction

This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease.

Methods

Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1 mg dose of lorazepam.

Results

Post-lorazepam, there were significant (P<0.05) declines from baseline in memory, psychomotor processing speed, and executive function. At 2.5 hours, the magnitude of this lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of working memory and visuospatial memory/e

SUBMITTER: Stonnington CM 

PROVIDER: S-EPMC5699956 | biostudies-literature | 2017 Oct-Dec

REPOSITORIES: biostudies-literature